Pacific Edge chief executive David Darling after launching
the company's Cxbladder e-commerce site. Photo supplied.
General practitioners in small New Zealand towns and
rural areas are likely to be keen users of the new Pacific Edge
e-commerce site, chief executive David Darling says.
The e-commerce site was launched yesterday, meaning all New
Zealand residents and healthcare professionals could access
the Cxbladder cancer detection technology developed by the
Dr Darling said there had been much talk about empowering
rural New Zealand through technology and the new Cxbladder
e-commerce site fitted ''nicely'' into the model.
''This will help emancipate those professionals who have few
technology tools to use.''
GPs in small towns often had barriers in treating some
However, they could now order the Cxbladder product online,
issue it to their patients and send it in for testing.
The goal was to make the tests easily available, he said.
New Zealanders would pay a rebated cost of $368 for a test,
much lower than the cost of a test in the United States.
Asked about the turnaround time for the tests, Dr Darling
said the company's brand promised a five-day turnaround and
he stood by the claim, even allowing for the possible two-day
delivery of the test kits.
''This all leads into an effective feed of information to
"The information is passed between the GP and the urologist
without having the patient coming in personally, in some
"For the patient, the information is more accessible.''
A cancer diagnosis was a stressful time but with the
Cxbladder test kits, blood in the urine could be tested,
allowing people to quickly receive information, he said.
To be able to collect a urine sample from the privacy of
their own home was a big step forward in the ability for
people wishing to take a more active role in providing their
healthcare professional with more information on their
Reaction from urologists to the new service had been positive
so far, Dr Darling said.
There had been concern from some urologists who had misread
an earlier statement and thought the results were being sent
directly to the patient, rather than the GP.
The results could only be obtained from medical
professionals, he said.
It was estimated there were close to 10,000 New Zealanders
per year who had haematuria leading to about 600 New
Zealanders a year with bladder cancer, responsible for about
170 deaths a year.
Pacific Edge Diagnostics commercial director Brent Pownall
said many patients with haematuria went through the
discomfort of a full medical work-up, often using invasive
tests, to determine if bladder cancer was present.
''Those who have been diagnosed with bladder cancer and need
ongoing monitoring of their condition know only too well the
benefits of using Cxbladder's testing system,'' he said.